Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics-Reference-Cited by-同舟云学术

Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics

Published:2020-10-27 Issue:21 Volume:63 Page:12574-12594
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hillisch Alexander¹^ORCID,Gericke Kersten M.¹,Allerheiligen Swen¹,Roehrig Susanne¹,Schaefer Martina²,Tersteegen Adrian¹,Schulz Simone¹,Lienau Philip²,Gnoth Mark¹,Puetter Vera²,Hillig Roman C.²,Heitmeier Stefan¹

Affiliation:

1. Research and Development, Bayer AG, Pharmaceuticals, 42103 Wuppertal, Germany

2. Research and Development, Bayer AG, Pharmaceuticals, 13342 Berlin, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01035

Reference50 articles.

1. Absorption, Distribution, Metabolism, and Excretion of Ximelagatran, an Oral Direct Thrombin Inhibitor, in Rats, Dogs, and Humans

2. Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors

3. Oral, Direct Thrombin and Factor Xa Inhibitors: The Replacement for Warfarin, Leeches, and Pig Intestines?

4. Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor

5. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling dynamics of nitrogen content and selected nitrogen heterocycles in thrombin inhibitors: a ceteris paribus approach;Expert Opinion on Drug Discovery;2024-06-19

2. Divergent Synthesis of Fluoroalkyl Ketones through Controlling the Reactivity of Organoboronate Complexes;Journal of the American Chemical Society;2024-02-01

3. Design, synthesis, and antiproliferative evaluation of novel dehydroabietic acid-1,2,3-triazole-oxazolidinone hybrids;RSC Medicinal Chemistry;2024

4. A facile route for highly enantioenriched six‐membered 1,4‐N,N‐ and N,O‐heterocycles from L‐serinate‐derived α‐bromoacetates;Bulletin of the Korean Chemical Society;2023-10-14

5. Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders;Journal of Medicinal Chemistry;2023-09-05